Concept
Tardive dyskinesia
Related publications (20)
Rational Design of Chemically Controlled Antibodies and Protein Therapeutics
Li Tang, Bruno Emanuel Ferreira De Sousa Correia, Sandrine Madeleine Suzanne Georgeon, Pablo Gainza Cirauqui, Anthony Marchand, Leo Scheller, Lucia Bonati, Stéphane Rosset, Sailan Shui
Protein-based therapeutics, such as monoclonal antibodies and cytokines, are important therapies for various pathophysiological conditions such as oncology, autoimmune disorders, and viral infections. However, the wide application of such protein therapeut ...
2023Depotentiation of associative plasticity is intact in Parkinson's disease with mild dyskinesia
Objective: Depotentiation of homosynaptic plasticity of the primary motor cortex (M1) is impaired in patients with Parkinson's disease (PD) who have developed dyskinesias. In this exploratory study, we tested whether this holds true for heterosynaptic plas ...
ELSEVIER SCI LTD2022Multi-centre classification of functional neurological disorders based on resting-state functional connectivity
Dimitri Nestor Alice Van De Ville, Jonas Richiardi
Background: Patients suffering from functional neurological disorder (FND) experience disabling neurological symptoms not caused by an underlying classical neurological disease (such as stroke or multiple sclerosis). The diagnosis is made based on reliable ...
ELSEVIER SCI LTD2022The shine-through paradigm and the schizophrenia spectrum: a summary
Michael Herzog, Simona Adele Garobbio, Maya Roinishvili, Ophélie Gladys Favrod
In the past 10 years, our laboratory has proved the shine-through paradigm to be a very sensitive endophenotype for schizophrenia. The shine-through paradigm is a visual backward masking task, where the target is a vertical vernier followed by a 25-element ...
2021Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease
To investigate whether the reversible MAO-B inhibitor and sodium channel blocker safinamide impairs glutamate release under parkinsonian conditions in vivo, and this effect is dependent on MAO-B inhibition, safinamide (and rasagiline as a comparator) were ...
PERGAMON-ELSEVIER SCIENCE LTD2020Structure of a D2 dopamine receptor-G-protein complex in a lipid membrane
Patrick Daniel Barth, Mahdi Hijazi
The D2 dopamine receptor (DRD2) is a therapeutic target for Parkinson's disease(1)and antipsychotic drugs(2). DRD2 is activated by the endogenous neurotransmitter dopamine and synthetic agonist drugs such as bromocriptine(3), leading to stimulation of G(i) ...
NATURE PUBLISHING GROUP2020Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients
Johannes Gräff, Jose Vicente Sanchez Mut, Aurélie Delacrétaz, Céline Dubath
Background: Metabolic side effects induced by psychotropic drugs represent a major health issue in psychiatry. CREB-regulated transcription coactivator 1 (CRTC1) gene plays a major role in the regulation of energy homeostasis and epigenetic mechanisms may ...
BMC2019Mining the Potential of Label-Free Biosensors for In Vitro Antipsychotic Drug Screening
Sandro Carrara, Hatice Altug, Tugba Kilic, Maria Soler Aznar
The pharmaceutical industry is facing enormous challenges due to high drug attribution rates. For the past decades, novel methods have been developed for safety and efficacy testing, as well as for improving early development stages. In vitro screening met ...
2018Inhaling xenon ameliorates l -dopa-induced dyskinesia in experimental parkinsonism
Grégoire Courtine, Eduardo Martin Moraud, Tomislav Milekovic, Shiqi Sun
Parkinson's disease motor symptoms are treated with levodopa, but long‐term treatment leads to disabling dyskinesia. Altered synaptic transmission and maladaptive plasticity of corticostriatal glutamatergic projections play a critical role in the pathophys ...
2018A novel psychoanalytical approach: An electrochemical ligand-binding assay to screen antipsychotics
Schizophrenia treatment may see a paradigm shift due to development of new atypical antipsychotic drugs (APDs), with better tolerability due to more selective dopamine (DA) receptor blockade. Monitoring of these APD candidates in biological fluids is of gr ...
2018